Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C VanCott

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Journal of Virology|May 11, 1999
Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelopeT C VanCott, J R Mascola, L D Loomis-Price, et al.
Journal of the American Geriatrics Society|April 20, 2010
Choice of initial antiepileptic drug for older veterans: possible pharmacokinetic drug interactions with existing medicationsMary Jo V Pugh, Anne C Vancott, Michael A Steinman, et al.
AIDS Research and Human Retroviruses|March 10, 1998
A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 cladesM K Gorny, J R Mascola, Z R Israel, et al.
Journal of Virology|January 9, 1999
Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virusM G Lewis, J Yalley-Ogunro, J J Greenhouse, et al.
Journal of Virology|October 6, 1997
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12J R Mascola, M K Louder, T C VanCott, et al.
Journal of Virology|June 1, 1997
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160T C VanCott, J R Mascola, R W Kaminski, et al.
Journal of Virology|March 9, 2000
Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvantsJ J Kim, J S Yang, T C VanCott, et al.
AIDS (London, England)|October 1, 1995
Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potentialJ D Fontenot, T C VanCott, B S Parekh, et al.
Epilepsia|December 5, 2008
New-onset geriatric epilepsy care: Race, setting of diagnosis, and choice of antiepileptic drugOmotola A Hope, John E Zeber, Nancy R Kressin, et al.
The Journal of Infectious Diseases|June 6, 2000
Lack of association between human immunodeficiency virus type 1 antibody in cervicovaginal lavage fluid and plasma and perinatal transmission, in ThailandR Chuachoowong, N Shaffer, T C VanCott, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Journal of Virology|May 11, 1999
Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelopeT C VanCott, J R Mascola, L D Loomis-Price, et al.
Journal of the American Geriatrics Society|April 20, 2010
Choice of initial antiepileptic drug for older veterans: possible pharmacokinetic drug interactions with existing medicationsMary Jo V Pugh, Anne C Vancott, Michael A Steinman, et al.
AIDS Research and Human Retroviruses|March 10, 1998
A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 cladesM K Gorny, J R Mascola, Z R Israel, et al.
Journal of Virology|January 9, 1999
Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virusM G Lewis, J Yalley-Ogunro, J J Greenhouse, et al.
Journal of Virology|October 6, 1997
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12J R Mascola, M K Louder, T C VanCott, et al.
Journal of Virology|June 1, 1997
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160T C VanCott, J R Mascola, R W Kaminski, et al.
Journal of Virology|March 9, 2000
Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvantsJ J Kim, J S Yang, T C VanCott, et al.
AIDS (London, England)|October 1, 1995
Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potentialJ D Fontenot, T C VanCott, B S Parekh, et al.
Epilepsia|December 5, 2008
New-onset geriatric epilepsy care: Race, setting of diagnosis, and choice of antiepileptic drugOmotola A Hope, John E Zeber, Nancy R Kressin, et al.
The Journal of Infectious Diseases|June 6, 2000
Lack of association between human immunodeficiency virus type 1 antibody in cervicovaginal lavage fluid and plasma and perinatal transmission, in ThailandR Chuachoowong, N Shaffer, T C VanCott, et al.
Pageof 8